Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies
View abstract on PubMed
Summary
This summary is machine-generated.High-dose statin pretreatment significantly reduces periprocedural myocardial infarction and 30-day adverse cardiac events in patients undergoing percutaneous coronary intervention (PCI). This effective strategy should be considered for all patients scheduled for PCI.
Area Of Science
- Cardiology
- Interventional Cardiology
- Pharmacology
Background
- Previous studies indicated statin pretreatment may reduce cardiac events post-percutaneous coronary intervention (PCI).
- However, existing data were largely observational, with limited evidence from randomized trials.
Purpose Of The Study
- To evaluate the efficacy of high-dose statin pretreatment in reducing periprocedural myocardial infarction and major adverse cardiac events (MACE) following PCI.
- To analyze the impact of statin pretreatment across various patient subgroups.
Main Methods
- A collaborative meta-analysis of individual patient data from 13 randomized trials involving 3341 patients undergoing PCI.
- Patients received either high-dose statin or no/low-dose statin pretreatment, with all receiving statin post-intervention.
- Outcomes assessed included periprocedural myocardial infarction and 30-day MACE (death, myocardial infarction, target-vessel revascularization).
Main Results
- High-dose statin pretreatment reduced periprocedural myocardial infarction by 44% (7.0% vs. 11.9%; OR 0.56, P<0.00001).
- 30-day MACE were significantly lower in the high-dose statin group (7.4% vs. 12.6%; P<0.00001), representing a 44% risk reduction.
- Benefits were observed across subgroups, with a notably greater reduction in patients with elevated baseline C-reactive protein levels (68% risk reduction).
Conclusions
- High-dose statin pretreatment is a highly effective strategy for reducing periprocedural myocardial infarction and 30-day adverse events in patients undergoing PCI.
- This pretreatment approach should be strongly considered for all patients planned for percutaneous coronary intervention.